306 related articles for article (PubMed ID: 27033193)
1. Recent Advances in Nanosystems and Strategies for Managing Leishmaniasis.
Vaghela R; Kulkarni PK; Osmani RAM; Bhosale RR; Naga Sravan Kumar Varma V
Curr Drug Targets; 2017; 18(14):1598-1621. PubMed ID: 27033193
[TBL] [Abstract][Full Text] [Related]
2. Nanostructured delivery systems with improved leishmanicidal activity: a critical review.
Bruni N; Stella B; Giraudo L; Della Pepa C; Gastaldi D; Dosio F
Int J Nanomedicine; 2017; 12():5289-5311. PubMed ID: 28794624
[TBL] [Abstract][Full Text] [Related]
3. Nanotechnology based solutions for anti-leishmanial impediments: a detailed insight.
Jamshaid H; Din FU; Khan GM
J Nanobiotechnology; 2021 Apr; 19(1):106. PubMed ID: 33858436
[TBL] [Abstract][Full Text] [Related]
4. Application of nanotechnology in treatment of leishmaniasis: A Review.
Akbari M; Oryan A; Hatam G
Acta Trop; 2017 Aug; 172():86-90. PubMed ID: 28460833
[TBL] [Abstract][Full Text] [Related]
5. Promising nanotherapy in treating leishmaniasis.
de Souza A; Marins DSS; Mathias SL; Monteiro LM; Yukuyama MN; Scarim CB; Löbenberg R; Bou-Chacra NA
Int J Pharm; 2018 Aug; 547(1-2):421-431. PubMed ID: 29886097
[TBL] [Abstract][Full Text] [Related]
6. Drug delivery: lessons to be learnt from Leishmania studies.
Shaw CD; Carter KC
Nanomedicine (Lond); 2014 Jul; 9(10):1531-44. PubMed ID: 25253500
[TBL] [Abstract][Full Text] [Related]
7. Enhanced paromomycin efficacy by solid lipid nanoparticle formulation against Leishmania in mice model.
Heidari-Kharaji M; Taheri T; Doroud D; Habibzadeh S; Badirzadeh A; Rafati S
Parasite Immunol; 2016 Oct; 38(10):599-608. PubMed ID: 27213964
[TBL] [Abstract][Full Text] [Related]
8. Strategies for the design of orally bioavailable antileishmanial treatments.
Pham TT; Loiseau PM; Barratt G
Int J Pharm; 2013 Sep; 454(1):539-52. PubMed ID: 23871737
[TBL] [Abstract][Full Text] [Related]
9. Limitations of Current Therapeutic Options, Possible Drug Targets and Scope of Natural Products in Control of Leishmaniasis.
Tiwari N; Gedda MR; Tiwari VK; Singh SP; Singh RK
Mini Rev Med Chem; 2018; 18(1):26-41. PubMed ID: 28443518
[TBL] [Abstract][Full Text] [Related]
10. Nanotechnological strategies for the treatment of neglected diseases.
Khalil NM; de Mattos AC; Carraro TC; Ludwig DB; Mainardes RM
Curr Pharm Des; 2013; 19(41):7316-29. PubMed ID: 23489208
[TBL] [Abstract][Full Text] [Related]
11. Promising therapeutic targets for antileishmanial drugs.
Werbovetz KA
Expert Opin Ther Targets; 2002 Aug; 6(4):407-22. PubMed ID: 12223057
[TBL] [Abstract][Full Text] [Related]
12. Nanotechnological Strategies for Treatment of Leishmaniasis--A Review.
de Almeida L; Terumi Fujimura A; Del Cistia ML; Fonseca-Santos B; Braga Imamura K; Michels PAM; Chorilli M; Graminha MAS
J Biomed Nanotechnol; 2017 Feb; 13(2):117-33. PubMed ID: 29376626
[TBL] [Abstract][Full Text] [Related]
13. Development and evaluation of a cedrol-loaded nanostructured lipid carrier system for in vitro and in vivo susceptibilities of wild and drug resistant Leishmania donovani amastigotes.
Kar N; Chakraborty S; De AK; Ghosh S; Bera T
Eur J Pharm Sci; 2017 Jun; 104():196-211. PubMed ID: 28400285
[TBL] [Abstract][Full Text] [Related]
14. Drug resistance in leishmaniasis: current drug-delivery systems and future perspectives.
Yasinzai M; Khan M; Nadhman A; Shahnaz G
Future Med Chem; 2013 Oct; 5(15):1877-88. PubMed ID: 24144417
[TBL] [Abstract][Full Text] [Related]
15. Treatment of leishmaniasis: a review and assessment of recent research.
Elmahallawy EK; Agil A
Curr Pharm Des; 2015; 21(17):2259-75. PubMed ID: 25543123
[TBL] [Abstract][Full Text] [Related]
16. Challenges in drug discovery targeting TriTryp diseases with an emphasis on leishmaniasis.
Alcântara LM; Ferreira TCS; Gadelha FR; Miguel DC
Int J Parasitol Drugs Drug Resist; 2018 Dec; 8(3):430-439. PubMed ID: 30293058
[TBL] [Abstract][Full Text] [Related]
17. Antimicrobial peptides for leishmaniasis.
Cobb SL; Denny PW
Curr Opin Investig Drugs; 2010 Aug; 11(8):868-75. PubMed ID: 20721829
[TBL] [Abstract][Full Text] [Related]
18. Polymeric colloidal particulate systems: intelligent tools for intracellular targeting of antileishmanial cargos.
Asthana S; Gupta PK; Chaurasia M; Dube A; Chourasia MK
Expert Opin Drug Deliv; 2013 Dec; 10(12):1633-51. PubMed ID: 24147603
[TBL] [Abstract][Full Text] [Related]
19. Nanotechnology-aided diagnosis, treatment and prevention of leishmaniasis.
Kammona O; Tsanaktsidou E
Int J Pharm; 2021 Aug; 605():120761. PubMed ID: 34081999
[TBL] [Abstract][Full Text] [Related]
20. Innovative Solutions for the Control of Leishmaniases: Nanoscale Drug Delivery Systems.
Wagner V; Minguez-Menendez A; Pena J; Fernández-Prada C
Curr Pharm Des; 2019; 25(14):1582-1592. PubMed ID: 31223081
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
